BofA lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $14 from $17 and keeps a Neutral rating on the shares. While political and rate uncertainty continues to be an overhang, the firm ...
ROUNDUP BOYS BASKETBALL In a Commonwealth Athletic Conference matchup, Dalton Kinnon (17 points) and Chris Janvier (13 points ...